Navigation Links
Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
Date:9/13/2011

NEW YORK and MUNICH, September 13, 2011 /PRNewswire/ --


Chemosaturation Demonstrates Clinically Meaningful Tumor Response with Unresectable Neuroendocrine Tumors in the Liver  

Delcath Systems, Inc. (NASDAQ: DCTH) announced that updated results from the metastatic neuroendocrine tumor (mNET) cohort of the Company's recently completed Phase 2 clinical trial were presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) congress held this week in Munich, Germany. James F. Pingpank, MD, FACS, Associate Professor of Surgery at the University of Pittsburgh School of Medicine and a Principal Investigator of the Phase 2 trial, presented the late-breaking abstract on September 12, 2011at 4:45pm during an Oncologic Intervention oral abstract session.

In the Phase 2 trial's mNET cohort, 24 patients with unresectable mNET in the liver underwent an average of 3 chemosaturation procedures with concentrated melphalan and subsequent extra-corporeal venous hemofiltration. The primary endpoint of overall hepatic response rate (ORR) among the 20 evaluable patients was 70%, including one patient who presented with a confirmed complete response (CR) and 13 with confirmed partial responses (PR). Four patients had stable disease (SD) and 2 progressed at their first evaluation, giving a tumor growth control rate of 90%. As for secondary endpoints, the median overall survival in all 24 patients (on an intent to treat or ITT basis) was reported as 30.4. months. The safety profile of the chemosaturation system was consistent with that previously reported for the Company's Phase 3 melanoma trial.

"Currently available treatment options for patients with unresectable neuroendocrine liver metastases have response rates around 5%. The anti-tumor activity and duration of response seen in the mNET arm of this Phase 2 study is very po
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
2. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
3. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
4. Ondine Announces Presentation of Positive Clinical Trial Results at the American Academy of Periodontologys 94th Annual Meeting
5. Positive SPA Reply From the FDA for TopoTargets Pivotal Trial With Belinostat in PTCL
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
8. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
9. Kuvan Receives Positive Opinion From CHMP for European Approval
10. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
11. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... (PRWEB) October 26, 2014 The ... Routers, ADC, Network Security Equipment, WAN Optimization Appliances]: ... and segments the data center networking market into ... of revenues. The report also identifies the factors ... opportunities impacting it along with the future roadmaps. ...
(Date:10/25/2014)... 24, 2014 According to new ... Data Center Types (Colocation, Enterprise, Telecom), by Design ... 1, Tier 2, Tier 3, Tier 4) - ... and segments the Data Center Construction Market into ... of revenues. This research report also identifies the ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in minimally ... that its Board of Directors has appointed Dr. ... and member of the Board effective immediately. In ... responsibilities within the company, including further developing the ... manufacturing and finance. , Dr. Carol joined ...
(Date:10/25/2014)... -- RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") ... Symposium on Thymosins in Health and Disease in ... thymosin beta 4 (TB4) linked with rhodamine (a fluorescent ... a rodent model of stroke, it was visualized outside ... functional tissue of the brain).   The leakage of TB4 ...
Breaking Biology Technology:Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2
... more convenient security to residences and private offices with their state-of-the-art ... businesses, hospitals, schools and the military is now accessible to the ... ... same innovative biometric technology used to enhance Hollywood films like Mission ...
... 27 MichBio, the association for,Michigan,s biosciences industry, ... to its program on day one of its ... Rock Financial ShowPlace Novi, MI. The,event will provide ... bioscience technologies and emerging companies to an audience ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today the company,s,participation and ... investor conferences in September., Conference: NewsMakers ... Millennium Broadway Hotel & Conference Center ... West 44th Street, New York Presentation Date: Thursday, September ...
Cached Biology Technology:BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices 2Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo 2Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation 2Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation 3
(Date:10/29/2014)... EAST LANSING, Mich. – As bodies decompose, their ... Deciphering the clues they provide could mean the ... murder. , Michigan State University is using a ... to help Detroit death-scene investigators examine these changing ... such as geographical location of death, gender, race, ...
(Date:10/29/2014)... Virtually all organisms in the living world compete ... differ strongly in how much they invest into ... and eager to get access to high-quality resources, ... prudent use of the lower-quality resources that are ... competitiveness in animal and human societies seems to ...
(Date:10/28/2014)... news release is available in German . ... close relatives, the chimpanzees, acquire sufficient food when times ... National Park in Côte d,Ivoire researchers of the Max ... a clear example of how great apes can acquire ... show that chimpanzees make their sleeping nests more en ...
Breaking Biology News(10 mins):MSU partners with Detroit to investigate death scenes 2Evolution of competitiveness 2Evolution of competitiveness 3The early chimp gets the fig 2The early chimp gets the fig 3
... 2007Professor Gilles Gauthier of Universit Lavals Centre dtudes nordiques ... up the ArticWOLVES project as part of International Polar ... the research project aims to better understand the impact ... polar ecosystems. Dating back to the 1960s, Centre ...
... 24, 2007) New research published in the October ... Surgeons suggests that pregnant women suspected of having appendicitis ... the appendix) that can result in early delivery or ... the need to require more accurate diagnosis to avoid ...
... The vast majority of patients who had ... did not need mitral valve surgery three years ... improved function of the left ventricle (commonly known ... week at the Cardiovascular Research Foundations (CRF) nineteenth ...
Cached Biology News:$2.8 million for research into the impact of climate change on tundra wildlife 2Pregnant women at risk for unnecessary operations due to misdiagnosis of appendicitis 2New data shows benefits of MitraClip for patients with mitral regurgitation 2New data shows benefits of MitraClip for patients with mitral regurgitation 3
MAb to Mouse MHC Class I H-2Kd...
... Agarose Gel-Digesting Preparation contains a unique β-agarose ... quantitative recovery of intact DNA and RNA ... following electrophoresis in TAE, TBE, MOPS, or ... directly in the TAE, TBE, MOPS, and ...
... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
... is causing shortages in your laboratory or ... can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us ... up and market it internationally. We work ...
Biology Products: